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1. ABSTRACT 
Angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma, not 
otherwise specified (PTCL-NOS) are subtypes of T-cell lymphoma. Due to low tumor 
cell content and substantial reactive cell infiltration, these lymphomas are sometimes 
mistaken for other types of lymphomas or even non-neoplastic diseases. In addition, a 
significant proportion of PTCL-NOS cases reportedly exhibit features of AITL 
(AITL-like PTCL-NOS). Thus disagreement is common in distinguishing between 
AITL and PTCL-NOS. Using whole-exome and subsequent targeted sequencing, our 
group recently identified G17V RHOA mutations in 60-70% of AITL and AITL-like 
PTCL-NOS cases but not in other hematologic cancers, including other T-cell 
malignancies. Here, I establish a sensitive detection method for the G17V RHOA 
mutation using a quantitative allele-specific polymerase chain reaction (qAS-PCR) 
assay. Mutated allele frequencies deduced from this approach were highly correlated 
with those determined by deep sequencing. This method could serve as a novel 
diagnostic tool for 60-70% of AITL and AITL-like PTCL-NOS. 
 
2. INTRODUCTION 
2.1 G17V RHOA mutation is highly specific to AITL. 
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Based on the classification proposed by the World Health Organization (WHO), 
Angioimmunoblastic T-cell lymphoma (AITL) is a distinct subtype of T-cell lymphoma 
that accounts for 20% of peripheral T-cell lymphoma cases[1]. AITL is characterized by 
generalized lymphadenopathy, hyperglobulinemia, and autoimmune-like 
manifestations[1,2]. Pathologic examination of AITL tumors reveals polymorphous 
infiltration of reactive cells, including endothelial venules and follicular dendritic 
cells[3,4]. Based on gene expression profiling and immunohistochemical staining, the 
normal counterparts of AITL tumor cells are proposed to be follicular helper T cells 
(TFHs)[5]. Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a more 
heterogenous type of lymphoma, one that shows variation even in CD4 and CD8 
expression. Some PTCL-NOS cases share features of AITL, such as 
immunohistochemical staining patterns resembling those seen in AITL (AITL-like 
PTCL-NOS)[6] 
 
2.2 Difficulty of diagnose AITL. 
Expertise is required to diagnose AITL and PTCL-NOS because generally low 
tumor cell content obscures the neoplastic nature of some cases, and large reactive 
B-cells are often confused with tumor cells[7]. Clonal rearrangement of the T-cell 
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receptor gene is undetectable in 10-25% of AITL cases due to low tumor cell 
frequency[1]. In addition, clonal growth of Epstein-Bar virus-infected B-cells is not 
uncommon in these kinds of cancers, causing detection of clonal immunoglobulin gene 
rearrangement in 20% of these case.[1] 
 
2.3 G17V RHOA mutation is highly specific to AITL. 
Mutations in TET2, IDH2, and DNMT3A are frequently seen in AITL and 
AITL-like PTCL-NOS[8,9], although these mutations are also common to various 
myeloid malignancies[10,11]. Our group and others reported a large cohort of AITL and 
PTCL-NOS patients revealing that the G17V RHOA mutation was highly specific to 
AITL and AITL-like PTCL-NOS and very frequent (seen in 60-70% of cases) in these 
T-cell lymphomas[12,13]. This observation suggests that detection of the G17V RHOA 
mutation could serve as a new diagnostic tool to discriminate these lymphomas from 
other diseases. One difficulty, however, is that RHOA mutation allele frequencies in 
these lymphomas are generally as low as <0.2 or often <0.1, reflecting low tumor cell 
content. Therefore, diagnosis of these conditions requires development of sensitive and 
cost-efficient methods that are as accurate as deep sequencing, which is expensive and 
not commonly used in most clinical testing facilities.
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To meet this need, I developed a quantitative allele-specific polymerase chain 
reaction (qAS-PCR) method that sensitively detects the G17V RHOA mutation in a 
highly accurate manner. This assay should provide a realistic way to conduct laboratory 
testing to diagnose AITL and AITL-like PTCL-NOS.     
   
3. MATERIALS AND METHODS 
3.1 Primer design 
I designed several types of forward primers that discriminate wild-type (WT) from 
G17V RHOA for use with one common reverse primer. One mutant forward primer was 
designed using a previously described algorithm[14]. The 3’ end is specific to the 
mutant site and an internal mismatch at the second nucleotide from the 3’ end was 
introduced to improve specificity (Figure 1 and Table 1). Other primers are designed as 
0bp, 2bp and 3bp-changed from mutant and WT sequences. 
 
3.2 Preparation of plasmids containing WT and mutant cDNA and standard curve 
generation 
WT or G17V mutant RHOA cDNA was subcloned into pBluescript (pBS/wtRHOA 
or pBS/mutRHOA, respectively; Agilent Technologies, Santa Clara, CA). qPCR 
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reactions were performed in a final volume of 20 μl using 10 nM primers and the 
SYBR-Green mix (Roche Applied Science, Mannheim, Germany), and amplicons were 
subjected to either the ABI7500 or 7900 Fast Sequence Detection Systems (Life 
Technologies, Carlsbad, CA). Use of either the WT or mutant forward primer plus the 
common primer generated a 73-bp PCR product. The following PCR conditions were 
used: 10 min at 95℃, followed by 40 cycles of 15 sec at 95℃ and 60 sec at 60℃.  
Standard curves of amplicon levels were created by qPCR using serially-diluted 
pBS/wtRHOA or pBS/mutRHOA with WT or mutant primers, respectively. 
 
3.3 Preparation of template plasmid DNA mixtures 
pBS/mutRHOA was mixed with pBS/wtRHOA in 100, 10, 1.0, 0.1, 0.01 and 0% 
ratios. Overall DNA concentration was adjusted to 1.0 ng/well of a plate. All mixtures 
were then serially-diluted 1:10 for 4 cycles. qPCR was performed with these templates 
plus primers using conditions described above.  
 
3.4 Patients and samples 
Tumor samples were collected from 53 patients with AITL, 55 with PTCL-NOS, 19 
with B-cell malignancies, 129 with myeloid malignancies, and 5 with another T-cell 
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lymphoma (for a total of 261), according to WHO classification. Twenty-seven 
non-tumor samples, including bone marrow mononuclear cells and buccal cells from 
lymphoma patients, were also analyzed as controls. The Ethics Committee University of 
Tsukuba Hospital approved the protocol and consent procedure, according to which 
written informed consent was provided by the participants. Genomic DNA was 
extracted from 13 formalin-fixed/paraffin-embedded (FFPE), 47 
periodate/lysine/paraformaldehyde (PLP)-fixed, and 228 fresh frozen specimens, using 
an FFPE tissue kit (QIAGEN, Hilden, Germany) for FFPE and PLP samples and a 
Puregene DNA blood kit (QIAGEN) for fresh frozen specimens, according to 
manufacturer’s instructions.  
One hundred and one DNA samples were original, while 187 were whole 
genome-amplified by either GenomiPhi (GE, Fairfield, CT) or a RepliG mini kit 
(Qiagen) (Table 2). For DNA extracted from FFPE samples, I also prepared PCR 
amplicon with AmpliTaq Gold 360 (Life technologies) in a final volume of 20 μl with 
20 ng genomic DNA, 5 nM primers (Table 3), 5μl of AmpliTaq gold master mix, and 
0.3μl of 360 GC Enhancer. For this amplicon preparation, the following PCR conditions 
were used: one cycle of 15 min at 95℃, 4 min at 60℃, and 1 min at 72℃, next 35 
cycles of 1 min at 95℃, 1 min at 60℃, and 1min at 72℃, and finally 10 min at 72℃ 
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and kept at 4℃. Amplicons were purified using PCR purification kit (QIAGEN). 
Each DNA sample was quantified using the Qubit dsDNA HS Assay kit and a Qubit 
fluorometer (Life Technologies, Carlsbad, CA). Extracted DNA samples were stored at 
-20℃ until use. 
For 108 of the total 288 genomic DNA samples, data sets for mutant allele 
frequencies obtained by deep sequencing using the MiSeq System (Illumina, San Diego, 
CA), which were used in our previous report[12], were reanalyzed. 
 
3.5 qPCR of patient samples 
qPCR reactions using duplicate patient samples were performed in a final volume of 
20 μl with 50 ng of original or whole genome-amplified genomic DNA or 1.0×10-2 ng 
PCR-amplified DNA as a template, 10 nM primers, and the SYBR-Green mix (Roche, 
Basel, Switzerland) in conditions similar to those used for plasmid templates described 
above.  
Levels of amplicons generated using either the WT or mutant primer, calculated 
with reference to respective standard curves, were designated [wt] and [mut], 
respectively. 
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3.6 Statistical analysis 
Statistical analysis was conducted using SPSS software (Japan International 
Business Machines Corporation, Tokyo). A P-value <0.05 was considered statistically 
significant. 
 
4. RESULTS  
4.1 Primer specificity  
I performed qPCR with pBS/mutRHOA and pBS/wtRHOA using allele-specific 
primers I designed. I chose 2bp-changed mut and 0bp-changed WT primers as my 
qAS-PCR primer set because their specificities show the most similar results than other 
primers (Supplemental Figure 1). Melting curve analysis revealed that amplicons 
generated using either WT or mutant primers melted at 76.8℃ or 75.3℃, respectively. 
Non-specific amplicons were not observed in either pBS/wtRHOA/WT primer or 
pBS/mutRHOA/mutant primer combinations (Figures 2A and 2B).  
 
4.2 Linearity of amplicon generation  
I then varied either the ratio of pBS/mutRHOA to pBS/wtRHOA or the 
concentration of total input DNA, and measured the amounts of PCR product generated 
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using the mutant primer. Because I observed a nearly linear relationship between the 
amounts of generated amplicon and input DNA in the range of 10
4
 (1-0.0001 ng 
DNA/well) at each ratio of pBS/mutRHOA to pBS/wtRHOA (Figure 3A), I defined the 
amount of amplicon derived from 100% pBS/mutRHOA template at 0.1 ng/well as 0.1 
unit, and tested whether linearity was maintained with varying ratios of pBS/mutRHOA 
to pBS/wtRHOA. The template samples of 0.1 ng/well containing 10, 1, 0.1, and 0.01% 
pBS/mutRHOA were measured as 1.0×10
-2
 unit (C.I. (confidence interval), 
0.8-1.3×10
-2
; S.F. (scaling factor), 0.95-1.06), 1.2×10
-3 
unit (C.I., 0.8-1.6 x 10
-3
; S.F., 
0.96-1.07), 2.2×10
-4
 unit (C.I., 1.5-3.0×10
-4
; S.F., 1.05-1.14), and 1.0×10
-5
 unit (C.I., 
0.4-1.6 x 10
-5
; S.F., 0.92-1.04), indicative of linearity in the range of 10
4
 (100-0.01%). 
Taken together, linearity was maintained in the range of 10
9
 (Figures 3A and 3B).  
Similarly, when I assessed the WT primer using various ratios of pBS/wtRHOA to 
pBS/mutRHOA and concentrations of input DNA, linearity between the amounts of 
amplicon and template were maintained between 100-0.1% (a range of 10
3
) and 1-0.001 
ng DNA/well (a range of 10
3
). This analysis indicated a total dynamic range of 106 
(Figures 3C and 3D).  
 
4.3 qAS-PCR of T-cell lymphoma samples 
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qAS-PCR with 50ng of genomic DNA was performed using 106 AITL and 
PTCL-NOS samples including 11 FFPE samples. The [wt] and [mut] values were 
distributed between 7.9×10
-5 
and 1.8×10
-1
 units, and 2.0×10
-7
 and 7.6×10
-2
 units, 
respectively. Nevertheless, it was not possible to use absolute values of [mut] for levels 
of G17V RHOA alleles, due to variation in DNA quality. Therefore, I undertook relative 
measures to assess G17V RHOA allele frequency. To do so, I calculated a 
[mut]/([wt]+[mut]) value and compared it with mutant variant allele frequencies 
determined by MiSeq. [mut]/([wt]+[mut]) values were distributed between 3.2×10
-4
 and 
3.0×10
-1
. Among samples judged to harbor a G17V RHOA mutation by deep sequencing 
using the MiSeq System (cut-off level, 0.02), which was defined in previous paper[12], 
[mut]/([wt]+[mut]) values of DNA from MiSeq-positive FFPE samples were 
significantly lower than those from other MiSeq-positive samples (Miseq-positive FFPE 
vs MiSeq-positive other samples; 1.56×10
-2
 vs. 9.38×10
-2
, p<0.05, Student's t-test) 
(Figure 4A). Four out of all 8 MiSeq-positive FFPE samples were negative by 
qAS-PCR. Therefore, I excluded FFPE samples and analyzed data from 95 DNA 
samples that had been purified from PLP-fixed or frozen tissues.  
When [mut]/([wt]+[mut]) values were compared with mutant variant allele 
frequencies determined by MiSeq, the rank correlation coefficient was 0.785 
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(Spearman’s correlation P<0.001) (Figure 4B and C). Among the 95 samples analyzed, 
38 (29 AITL and 9 PTCL-NOS) were judged positive and 57 (14 AITL and 43 
PTCL-NOS) were judged negative by MiSeq. By comparison, when the cut-off level for 
[mut]/([wt]+[mut]) values was set at 1.5×10
-2
, according to ROC curve (Supplemental 
Figure 2), 38 cases were judged positive for the G17V RHOA mutation, including 29 
AITL and 9 PTCL-NOS. Overall, 91 of 95 specimens showed concordant results using 
both methods, while 4 cases showed discordant results (Figure 4B and C). If I assume 
that data generated by MiSeq is accurate, then the sensitivity and specificity of 
qAS-PCR were as high as 94.7% and 96.5%, respectively. Positive and negative 
concordance rates of the two methods were 94.7% and 96.5%, respectively (Table 4, 
Supplemental Table 1). 
The four cases showing discordant results provided us with an insight into the 
comparison between MiSeq and aAS-PCR. Two samples were positive only based on 
MiSeq, and two were positive only by qAS-PCR. When I performed HISEQ2000 
sequencing[12] for all these four samples, I observed ≧0.02 mutation allele frequencies 
in two samples. One had been deemed positive only by qAS-PCR and the other only by 
MiSeq. The other two samples showed <0.02 mutation allele frequencies by 
HISEQ2000. One of them was judged as negative only by qAS-PCR and the other only 
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by MiSeq. Overall, accuracy with qAS-PCR and MiSeq was comparable.  
The qAS-PCR method using 50 ng of whole-genome-amplified DNA did not 
provide a robust correlation with the Miseq data for FFPE samples. The main reason 
was likely to be fragmentation of genomic DNA. To overcome this limitation, DNA 
prepared from the 13 FFPE samples was pre-amplified by PCR prior to performing 
qAS-PCR. Sensitivity and specificity for FFPE samples using amplicon was 87.5% and 
80.0%, respectively, based on the mutation allele frequencies determined by MiSeq. 
(Figure 4D, Supplemental Table 2). Therefore, even for FFPE samples, the qAS-PCR 
method could robustly estimate the G17V RHOA mutation allele frequencies. 
 
4.4 Effect of whole-genome amplification for qAS-PCR 
When I divided the 95 samples into original DNA and whole-genome-amplified 
DNA cohort, sensitivity and specificity were 100% and 95.5% for original DNA cohort, 
and 87.5% and 100% for whole-genome-amplified DNA cohort, respectively 
(Supplemental Figure 3A-D, Supplemental Table3A and B).  
In order to determine whether amplification influences the evaluation of mutation 
allele frequency by qAS-PCR, I compared the data for 15 pairs of original and 
whole-genome-amplified samples. Fourteen out of 15 pairs showed concordant results 
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with each other (Supplemental Table 3C and D, Supplemental Figure 3E). One sample, 
which was judged positive by MiSeq, showed discordant results by qAS-PCR; positive 
for the original DNA and negative for the whole-genome-amplified DNA. As a 
summary, with some limitations, whole-genome-amplified DNA could provide robust 
results in most cases. 
 
4.5 Comparison of the data with different PCR platforms 
In order to evaluate the influence of the difference between the PCR platforms, I 
compared the data for 8 (5 G17V RHOA positive and 3 negative) samples evaluated 
with 7500 Fast and 7900 Fast systems (Supplemental Figure 4). Both systems provided 
concordant results for all the 8 samples, indicating that the qAS-PCR values were 
reproducible with different platforms. 
 
4.6 qAS-PCR for myeloid, B-cell and other T-cell malignancies 
I performed qAS-PCR for buccal cells and non-tumor samples including bone 
marrow cells without lymphoma infiltration obtained from lymphoma patients, and 
confirmed that the qAS-PCR values were below the cut-off level in all samples. Then, I 
applied qAS-PCR for 153 tumor samples other than AITL and PTCL-NOS, including 
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129 myeloid, 19 B-cell, and 5 T-cell malignancies. Sanger sequencing also showed no 
mutant signals for any of these samples. All qAS-PCR values calculated using these 
samples were below the cut-off level (Figure 5). 
 
5. DISCUSSION 
Our recent discovery of the highly frequent G17V RHOA mutation in AITL and 
AITL-like PTCL-NOS led us to develop a novel method to detect this mutation[12]. 
The results of qAS-PCR analysis described here are correlated well with those derived 
from deep sequencing (Table 4), while qAS-PCR is superior to deep sequencing in 
terms of the cost and convenience. There is a pressing clinical need for a well-validated 
RHOA testing method with optimal analytical performance using the least amount of 
difficult-to-obtain patient specimens. I show here that even DNA samples subjected to 
whole-genome amplification or low quality/concentration DNA extracted from FFPE 
samples can serve as reliable material for our qAS-PCR method, if appropriate PCR 
procedure and primers are used. Allele-specific PCR for G17V RHOA mutation was 
mentioned in other report[13], although sensitivity and specificity of the methods were 
not described. 
  In a previous study, we defined the cut-off level of mutant allele frequencies 
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determined by MiSeq as 0.02[12]. In this study, I defined the cut-off level as 1.5×10
-2
 
for qAS-PCR, but it remains to be determined whether these cut-off levels are sufficient 
to detect AITL. Given our finding that the mutated RHOA allele frequencies distributed 
below 0.05 in many AITL samples[12], the tumor cell content might be very low and 
could be detected in some cases only when the cut-off levels of qAS-PCR and deep 
sequencing are lowered. If I set the cut-off value lower, the sensitivity should be 
improved with the increase of false-positive results, raising a dilemma common to other 
clinical testings. 
Several hotspot mutations that reveal distinct hematologic malignancies have been 
identified in conditions other than T-cell lymphomas. For example, detection of the 
V617F JAK2 mutation is a part of the diagnostic criteria for myeloproliferative 
neoplasms in the latest version of WHO classification[1], although consensus is not 
reached about the detection methods and cut-off levels. Methods have been developed 
to detect this mutation including allele-specific PCR and a PCR-restriction fragment 
length polymorphism (RFLP) approach utilizing mutation sequence specificity for a 
restriction enzyme[15-18]. More recently, a V600E BRAF mutation in hairy cell 
leukemia[19], an L265P MYD mutation in Waldenström macrogloblinemia[20], and 
several mutations in STAT3 in large granular lymphocytic leukemia[21] have been 
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identified as diagnostics of these tumor types. In the future, it is likely that molecular 
alterations, including the G17V RHOA mutation, will be increasingly incorporated into 
the diagnostic criteria for hematologic malignancies. In summary, our novel method to 
detect the G17V RHOA mutation could provide an important clinical tool to diagnose 
AITL and AITL-like PTCL-NOS and in the future serve as a means to classify AITL 
and PTCL-NOS.  
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Figure. 4 
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Figure .5 
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8.2 FIGURE LEGENDS 
Figure 1. Design of primers used in the study.  
A WT allele-specific primer forward primer (Upper), a mutant allele-specific forward 
primer (Lower), and a common primer were designed. The 3’ end of the forward mutant 
primer was specific to the mutant site (G to T) and an internal mismatch at the second 
nucleotide from 3’ end (G to A) was introduced to improve specificity. 
  
Figure 2. Melting curve analysis. 
A. Melting curve constructed using WT allele-specific primers. 
B. Melting curve constructed using mutant allele-specific primer set.  
 
Figure 3. Standard curve showing linearity of quantitative allele-specific PCR.  
A standard curve was generated by serial dilution of WT or G17V cDNA that had been 
subcloned into pBluescript.  
A. Serial dilution of pBS/mutRHOA. Black dots correspond to 1.0×10
-9
 ～1.0 unit of 
mutant plasmid (duplicate samples). The titration slope is -3.550 and R
2
 is 0.996.  
B. pBS/mutRHOA was mixed with pBS/wtRHOA at 100%, 10%, 1.0%, 0.1%, 0.01% 
and 0%. Mix concentrations were adjusted to 1.0 ng/well and diluted 1:10 4 times for 
27 
 
quantitative PCR analysis with allele-specific mutant primers. Horizonal axis indicates 
the amount of DNA per well. Vertical axis indicates unit for each sample. 
Black dot, MUT 100%; open dot, MUT 10%; square, MUT 1%; open square, MUT 
0.1%; diamond, MUT 0.01%; triangle, MUT 0% (WT 100%) 
C. Serial dilution of pBS/wtRHOA. Black dots correspond to 1.0×10
-6
 ～1.0 unit of 
WT cDNA (duplicate samples). The titration slope is -4.256, and R
2
 is 0.998. 
D. pBS/wtRHOA was mixed with pBS/mutRHOA at 100%, 10%, 1.0%, 0.1%, 0.1% 
and 0%. Mix concentrations were adjusted to 1.0 ng/well and diluted 1:10 4 times for 
quantitative PCR analysis with WT allele-specific primers. 
Black dot, WT 100%; open dot, WT 10%; square, WT 1%; open square, WT 0.1%; 
triangle, WT 0% (MUT 100%) 
 
Figure 4. qAS-PCR of AITL and PTCL-NOS samples.  
A, Shown are [mut]/([wt]+[mut]) values for each sample. N, mutation negative 
determined by MiSeq; P, mutation positive determined by MiSeq; Amp, amplified; PLP, 
periodate/lysine/paraformaldehyde-fixed; FFPE, formalin-fixed/paraffin-embedded. 
B, Comparison of [mut]/([wt]+[mut]) values by qAS-PCR and mutant allele frequencies 
as determined by MiSeq for 95 original or whole genome-amplified DNA samples, 
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including 43 AITL and 52 PTCL-NOS. Cut-off values were determined as 1.5×10
-2
 for 
[mut]/([wt]+[mut]) by qAS-PCR and as 0.02 for mutant allele frequencies as 
determined by MiSeq. 
C, Comparison of [mut]/([wt]+[mut]) values by qAS-PCR and mutant allele frequencies 
as determined by MiSeq for 95 DNA samples in a log scales. 
D, Comparison of [mut]/([wt]+[mut]) values by qAS-PCR and mutant allele frequencies 
as determined by MiSeq for 13 FFPE PCR-amplicon samples. 
 
Figure 5. qAS-PCR for 275 tumor and control samples. 
qAS-PCR was performed for tumor samples, including 43 AITL (a), 52 PTCL-NOS (b), 
5 T-cell lymphoma other than AITL and PTCL-NOS (c), 19 B-cell lymphomas (d), 129 
myeloid malignancies (e) and 27 control samples (f).  
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9. TABLES 
Table 1: Sequence of allele-specific primers used for this study.  
Primer Sequence 
Forward (WT
*1
) ATTGTTGGTGATGGAGCCTGTGG 
Forward (MUT
*2
) ATTGTTGGTGATGGAGCCTGTAT 
Reverse (common) ACACCTCTGGGAACTGGTCCT 
*1
 WT, wild-type; 
*2
 MUT, mutant. 
 
Table 2: Analysis of genomic DNA samples.  
Disease 
Frozen 
amp*1 
Frozen 
not-amp*2 
PLP 
not-amp 
FFPE 
not-amp 
Total 
AITL 14 10 19 10 53 
PTCL-NOS 16 8 28 3 55 
B-cell lymphoma 1 18     19 
Myeloid malignancies 129       129 
Other T-cell lymphomas   5     5 
Control samples 27       27 
Total 187 41 47 13 288 
*1
 amp, amplified; 
*2
 not-amp, not-amplified. 
 
Table 3: Primer sequences for making PCR amplicons of FFPE samples.  
Primer Sequence 
Forward  GCCCCATGGTTACCAAAGCA 
Reverse GCTTTCCATCCACCTCGATA 
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Table 4: Correlation between qAS-PCR and MiSeq.  
Method Standard Samples N
*1
 RCC
*2
 Sensitivity Specificity PPV
*3
 NPV
*4
 
qAS-PCR MiSeq 
AITL 
and 
PTCL-
NOS 
non-FFPE 95 0.785 94.7 96.5 94.7 96.5 
 
original 66 0.735 100.0 95.5 91.7 100.0 
WGA
*5
 29 0.822 87.5 100.0 100 86.7 
FFPE
 *6
 13 0.919 87.5 80.0 87.5 80.0 
*1
 N, number; 
*2
 RCC, rank correlation coefficient; 
*3
 PPV, positive predictive value; 
*4
 
NPV, negative predictive value,
 *5 
WGA, whole-genome amplification. 
*6
FFPE, 
formalin-fixed/paraffin-embedded
 
 
mut primer WT primer 
2bp 
0bp 
2bp 
3bp 3bp 
Supplemental Figure 1 
Supplemental Figure 1. Specificities of designed allele-specific primers 
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Supplemental Figure 1. ROC curve for data of qAS-PCR and MiSeq 
Horizontal axis shows 1-specificity and Vertical axis shows sensitivity of qAS-PCR method compared to the data of MiSeq. 
  
Supplemental Figure 2 
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Supplemental Figure 3. Effect of whole-genome amplification for qAS-PCR 
A,  Comparison of [mut]/([wt]+[mut]) values by qAS-PCR and mutant allele frequencies as determined by MiSeq for 66 original    
   samples (linear). 
B,  Comparison of [mut]/([wt]+[mut]) values by qAS-PCR and mutant allele frequencies as determined by MiSeq for 66 original    
   samples (log scale) 
C,  Comparison of [mut]/([wt]+[mut]) values by qAS-PCR and mutant allele frequencies as determined by MiSeq for 29 whole- 
   genome amplified samples (linear). 
D,  Comparison of [mut]/([wt]+[mut]) values by qAS-PCR and mutant allele frequencies as determined by MiSeq for 29 whole- 
   genome amplified samples (log scale). 
E,  Comparison of [mut]/([wt]+[mut]) values by qAS-PCR for 15 pairs of original and whole-genome amplified samples in a log  
   scale. 
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Supplemental Figure 4 
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Supplemental Figure 4.  
Comparison of [mut]/([wt]+[mut]) values by 7900 Fast and 7500 Fast(linear). 
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Supplemental Tables 
 
Supplemental Table 1 
Comparison between [mut]/ ([wt]+[mut]) by qAS-PCR and allele frequency determined 
by MiSeq for original and whole-genome amplified samples. 
 
MiSeq+ MiSeq- Total 
qAS-PCR+ 36 2 38 
qAS-PCR- 2 55 57 
total 38 57 95 
 
 
Supplemental Table 2 
Comparison between [mut]/ ([mut]+ [wt]) by PCR amplicon-based qAS-PCR and 
mutant allele frequency determined by MiSeq for 13 FFPE samples. 
 
MiSeq+ MiSeq- total 
qAS-PCR+ 7 1 8 
qAS-PCR- 1 4 5 
total 8 5 13 
 
 
Supplemental Table 3 
A. Comparison between [mut]/ ([wt]+[mut]) by qAS-PCR and allele frequency 
determined by MiSeq for 66 original samples. 
 
MiSeq+ MiSeq- total 
qAS-PCR+ 22 2 24 
qAS-PCR- 0 42 42 
total 22 44 66 
 
B. Comparison between [mut]/ ([wt]+[mut]) by qAS-PCR and allele frequency 
determined by MiSeq for 29 whole-genome amplified samples. 
 
MiSeq+ MiSeq- total 
qAS-PCR+ 14 0 14 
qAS-PCR- 2 13 15 
total 16 13 29 
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C. Comparison between [mut]/ ([wt]+[mut]) by qAS-PCR and mutant allele frequency 
determined by MiSeq for 13 original sample. 
 
MiSeq+ MiSeq- Total 
qAS-PCR+ 6 0 6 
qAS-PCR- 0 9 9 
total 6 9 15 
 
D. Comparison between [mut]/ ([wt]+[mut]) by qAS-PCR and mutant allele frequency 
determined by MiSeq for 13 whole-genome amplified sample. 
 
MiSeq+ MiSeq- Total 
qAS-PCR+ 5 0 5 
qAS-PCR- 1 9 10 
total 6 9 15 
 
